The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Sharmilan Thanendrarajan, Eming Tian, Pingping Qu, Pankaj Mathur, Carolina Schinke, Frits van Rhee, Maurizio Zangari, Leo Rasche, Niels Weinhold, Daisy Alapat, William Bellamy, Cody Ashby, Sandra Mattox, Joshua Epstein, Shmuel Yaccoby, Bart Barlogie, Antje Hoering, Michael Bauer, Brian A Walker, Faith E Davies, and Gareth J Morgan

Disclosures: Bart Barlogie is a co-inventor on patents and patent applications related to use of GEP in cancer medicine that have been licensed to Signal Genetics Inc. The remaining authors declare no conflict of interest.

Contributions: GJM, ST and PQ developed concept, design and wrote the manuscript. PQ, AH and CA performed statistical analysis. ET, PM, CS, FVR, MZ, DA, BB, FED, SM provided study material and patient data. FVR, LR, NW, DA, WB, JE, SY, MB, BAW supported in interpretation of the results.